Stay up to date on the latest oncology and nursing conferences.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Patients with EGFR-mutated non–small cell lung cancer had a median event-free survival of 30.8 months in the durvalumab arm and 19.6 months in the placebo arm.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease.
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Quizartinib plus standard intensive induction and consolidation therapy was associated with longer survival rates in patients with FLT3-ITD–positive acute myeloid leukemia.
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
The confirmed objective response rate with repotrectinib was 79% among tyrosine kinase inhibitor (TKI)-naïve patients and 38% among TKI-pretreated patients.
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone.
Sacituzumab Govitecan/Pembrolizumab Shows Early Antitumor Activity in Metastatic NSCLC
The objective response rate with sacituzumab govitecan plus pembrolizumab was 56%.
Patritumab Deruxtecan Elicits Durable Responses in Pretreated EGFR-Mutated NSCLC
Patrimumab deruxtecan garnered a 29.8% overall response rate in pretreated patients with EGFR-mutated non–small cell lung cancer.
2-Year Follow-Up Supports Adagrasib Monotherapy in KRAS G12C–Mutant NSCLC
Adagrasib elicited a 1-year overall survival rate of 52.8% and 2-year rate of 31.3%.
Iruplinalkib Produces Longer PFS Than Crizotinib in Advanced ALK+ NSCLC
The median progression-free survival with iruplinalkib was 27.70 months vs 14.62 months with crizotinib.
Study Shows 5 Key Determinants of Health Drive Outcomes in Hematologic Malignancies
Although survival is improving overall, disparities continue to grow.
Luspatercept Continues to Improve RBC Transfusion Independence in Patients With MDS
A total of 58.5% of patients who received luspatercept remained red blood cell (RBC) transfusion independent for 12 weeks or more.
Intra-Arterial Gemcitabine Linked to OS Improvement Vs IV Gemcitabine/Nab-Paclitaxel in Locally Advanced Pancreatic Cancer
The median overall survival with intra-arterial gemcitabine was 15.7 months vs 10.1 months with intravenous gemcitabine and nab-paclitaxel.
Topical Diclofenac Gel Reduces Capecitabine-Related Hand-Foot Syndrome
Patients with breast and gastrointestinal cancers reported fewer hand-foot syndrome events following treatment with topical diclofenac gel.
Watch-and-Wait Approach Remains the Standard for Patients with Early-Stage CLL
Phase 3 findings from the CLL12 trial support a watch-and-wait approach over systemic treatment with ibrutinib for patients with asymptomatic early-stage chronic lymphocytic leukemia.
Liso-cel Demonstrates Rapid, Durable Responses in Patients with Relapsed/Refractory CLL/SLL
The phase 1/2 TRANSCEND CLL 004 trial met its primary end point by demonstrating that lisocabtagene maraleucel elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Talazoparib Plus Enzalutamide Significantly Improves PFS in Patients With HRR mCRPC
Talazoparib reduced the risk of progression or death by 55% in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
CDK4/6 Inhibitors May Be Better Suited in the Second-Line for Patients With ER+, HER2– Breast Cancer
Second-line treatment with CDK4/6 inhibition was associated with fewer toxicities and drug costs than frontline CDK4/6 inhibitor treatment—although progression-free survival and overall survival outcomes were similar.
Patients With nmCRPC Achieve Longer Treatment Duration With Darolutamide
The rates of treatment discontinuation were higher with enzalutamide and apalutamide than with darolutamide for patients with non-metastatic castration resistant prostate cancer.
Bevacizumab-Based Regimen Improves PFS in HRD-Negative Advanced Ovarian Cancer
Maintenance bevacizumab plus durvalumab and olaparib improved progression-free survival in patients with HRD-negative advanced ovarian cancer.
Atezolizumab Falls Short in Pretreated, Advanced Renal Cell Carcinoma
The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.
Elranatamab Induces Responses in Patients With Relapsed/Refractory Multiple Myeloma Following BCMA-Directed Therapy
Patients with relapsed/refractory multiple myeloma treated with elranatamab following any prior BCMA-directed therapy achieved an overall response rate of 46%.
Mediastinal Radiotherapy May be Safely Omitted Following Frontline Immunochemotherapy in PMBCL
Omitting radiotherapy did not compromise overall survival rates for patients with primary mediastinal B-cell lymphoma.
Elacestrant Shows PFS Benefit For Patients With ER+/HER2-, ESR1-Mutated Breast Cancer and Prior CDK4/6 Treatment History
Patients with ESR1 mutations who received 12 months or more of prior treatment with a CDK4/6 inhibitor achieved a median progression free survival of 8.61 months with elacestrant compared with 1.91 months for those given standard therapy.
Lower Trastuzumab Deruxtecan Dose Appears Optimal in HER2+ mCRC
Patients with HER2-positive, metastatic colorectal cancer derived clinical benefit from a 5.4 mg/kg dose of trastuzumab deruxtecan.
Quality Improvement Project Improves Timeliness of Antibiotic Administration in BMT Patients
Sabrina Banegas, RN, BMT-CN, highlights the value of improving antibiotic administration times for patients undergoing bone marrow transplant.
Frontline Enfortumab Vedotin/Pembrolizumab Shows Continued Efficacy in Advanced Urothelial Carcinoma at 4-Year Follow-Up
Enfortumab vedotin plus pembrolizumab elicited durable responses in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.
Machine Learning May Be Useful in Predicting AEs in Head and Neck Cancer
Meredith Cummings, BSN, RN, OCN, discusses the potential benefit of machine learning in predicting symptoms for patients with head and neck cancer.
Attune App Helps Patients Manage Cancer-Related Anxiety Symptoms
According to investigators, digitized cognitive behavioral stress management may help clinicians offer more comprehensive cancer care.
TROPiCS-02 Final OS Analysis Shows Superior Outcomes With Sacituzumab Govitecan For HR+/HER2– Breast Cancer
Sacituzumab govitecan improved overall survival vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.
Cilta-cel Showcases PFS Improvement Following First Relapse In Lenalidomide-Refractory Myeloma
Ciltacabtagene autoleucel improved progression-free survival vs pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with lenalidomide-refractory multiple myeloma.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512